M-M-RvaxPro vaccine clinical trials

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

This study is testing a new vaccine (PCV21) for healthy babies aged 2 to 4 months. It aims to see if it's safe and helps babies make germ-fighting antibodies against pneumococcal disease, comparing it to an existing vaccine alongside their routine immunisations.